71
Participants
Start Date
January 19, 2022
Primary Completion Date
November 30, 2024
Study Completion Date
November 30, 2024
(R)-1-(2-chlorophenyl)- N-[11C] ([11C] PK11195)
Radiotracer used during the PET-MR scan of the study to identify signs of disease. Used in studies related to Alzheimer's disease. Only FDA approved for investigational use.
2-(4-[11C]methylamino phenyl)-6-hydroxybenzothiazole (11C]6-OH-BTA-1 or [11C]PIB)
Radiotracer used during the PET-MR scan of the study to identify signs of disease. Used in studies related to Alzheimer's disease. Only FDA approved for investigational use.
Mayo Clinic Florida, Jacksonville
Lead Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Mayo Clinic
OTHER